The role of targeted therapy is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer (NSCLC), said D. Ross Camidge, MD, PhD, who added that among multiple therapeutic options for common aberrations, such as ALK, ROS1, BRAF, and MET, treatment selection should be based on more than just genetics.
“Molecular heterogeneity in NSCLC is here to stay,” said Camidge. “We are now getting into a situation where first-line choices for some targeted therapies have entered the field of luxury oncology where we have choices with similar or equivalent efficacies. Perhaps we are going to have to start making [treatment] choices based on toxicity, convenience, tolerability, drug-drug interactions, and cost.”
In an interview with OncLive® during the 2020 Institutional Perspectives in Cancer webinar on lung cancer, Camidge, professor of medicine-medical oncology at the University of Colorado (UC) School of Medicine and director of the Thoracic Oncology and Clinical Research Programs at the UC Hospital Cancer Center, discussed the current state of targeted therapy in NSCLC and factors to consider before ordering next-generation sequencing (NGS). Read the entire interview.